Regencell Bioscience Holdings (RGC) Assets (2020 - 2025)

Regencell Bioscience Holdings (RGC) reported Assets of $3.0 million for Q4 2025, down 47.64% quarter-over-quarter from $5.8 million in Q2 2025.

Regencell Bioscience Holdings (RGC) Assets (2020 - 2025) Analysis & Trends

Regencell Bioscience Holdings has reported Assets for 3 years, with the latest figure at $3.0 million in Q4 2025.

For the quarter ending Q4 2025, Assets changed N/A year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.8 million (changed N/A YoY), and the FY2025 full-year result was $5.8 million, changed N/A from the prior year.
Assets for Q4 2025 stood at $3.0 million, down from $5.8 million in the prior quarter.
The five-year high for Assets was $12.6 million in Q2 2023, with the low at $3.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	40.04 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	15.15 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	6.71 Bn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	555.95 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	4.91 Bn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	13.22 Bn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	4.26 Bn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	2.27 Bn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	2.35 Bn
10	Regencell Bioscience Holdings	-	-	-	3.01 Mn

Download Data